Principal Securities Inc. Reduces Stake in iShares Biotechnology ETF (NASDAQ:IBB)

Principal Securities Inc. lessened its position in iShares Biotechnology ETF (NASDAQ:IBB) by 18.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,089 shares of the financial services provider’s stock after selling 682 shares during the quarter. Principal Securities Inc.’s holdings in iShares Biotechnology ETF were worth $408,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Huntington National Bank lifted its stake in shares of iShares Biotechnology ETF by 17.9% in the 3rd quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock valued at $153,000 after purchasing an additional 160 shares during the period. National Bank of Canada FI lifted its stake in shares of iShares Biotechnology ETF by 5.9% in the 3rd quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock valued at $600,000 after purchasing an additional 229 shares during the period. Avior Wealth Management LLC lifted its stake in shares of iShares Biotechnology ETF by 438.2% in the 3rd quarter. Avior Wealth Management LLC now owns 3,229 shares of the financial services provider’s stock valued at $470,000 after purchasing an additional 2,629 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its position in iShares Biotechnology ETF by 32.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock valued at $96,533,000 after buying an additional 164,000 shares in the last quarter. Finally, Main Management ETF Advisors LLC increased its position in iShares Biotechnology ETF by 2.5% during the 3rd quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock valued at $86,395,000 after buying an additional 14,535 shares in the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Down 0.4 %

IBB stock opened at $138.91 on Friday. iShares Biotechnology ETF has a twelve month low of $123.60 and a twelve month high of $150.57. The business has a 50 day moving average of $135.61 and a 200 day moving average of $140.77.

iShares Biotechnology ETF Cuts Dividend

The business also recently disclosed a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were given a dividend of $0.0624 per share. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.